Welcome to our dedicated page for Perimeter Medical Imaging Ai news (Ticker: PYNKF), a resource for investors and traders seeking the latest updates and insights on Perimeter Medical Imaging Ai stock.
Perimeter Medical Imaging AI develops real-time optical coherence tomography imaging systems and artificial-intelligence tools for cancer surgery. The company’s Claire OCT+AI device has FDA premarket approval for intraoperative breast cancer margin assessment, while its S-Series OCT platform provides ultra-high-resolution cross-sectional visualization of excised tissue.
Company news commonly covers FDA regulatory milestones, product demonstrations, commercialization activity, clinical and technology updates, operating and financial results, investor conference presentations, and capital-structure actions such as private placements, warrants, and stock-option matters.
Perimeter Medical Imaging AI (OTCQX:PYNKF) has announced a strategic collaboration with Jennifer Douglas, a breast cancer survivor and influential patient advocate. Douglas will join the company's Industry Advisory Board (IAB) and support patient education initiatives.
Douglas, diagnosed with DCIS at 41, brings significant experience as an author and advocate, having written 'A Breast Cancer Journey: Living it One Step at a Time' and being recognized by the Dr. Susan Love Foundation. She will join existing IAB members including Diana Chan (Chair), Tom Boon, and Dr. Ted James, contributing to Perimeter's mission of improving breast cancer surgery outcomes through its OCT-based imaging platform.
Perimeter Medical Imaging AI (OTCQX:PYNKF) has joined the Industry Relations Council (IRC) of the American Society of Breast Surgeons (ASBrS), marking a strategic alliance in the breast surgery field. The ASBrS serves as the primary leadership organization for breast surgery specialists, focusing on excellence in patient care.
The company is currently commercializing its S-Series OCT system while awaiting FDA review of their PMA application for the next-generation AI-enabled B-Series OCT product. This membership positions Perimeter alongside established industry players in breast disease diagnosis and treatment.
Perimeter Medical Imaging AI (OTCQX:PYNKF) has appointed renowned surgical oncologist Dr. Ted James as Chief Medical Officer in a fractional role. Dr. James joins from his position as System Physician Executive of the Endeavor Health Cancer Institute and brings extensive experience from his previous role as Chief of Breast Surgical Oncology at Beth Israel Deaconess Medical Center.
Dr. James, who holds a Master of Science in Healthcare Management from Harvard and served as an Associate Professor of Surgery at Harvard Medical School, will help strengthen Perimeter's medical strategy and accelerate the adoption of its AI-enabled technology for margin assessment in breast cancer surgery. His appointment comes at a crucial time as the company works toward FDA approval of its next-generation AI-enabled Perimeter B-Series.
[ "Appointment of highly qualified CMO with extensive surgical oncology and leadership experience", "Strategic addition to advance FDA approval process for B-Series technology", "New CMO brings Harvard Medical School and Beth Israel Deaconess Medical Center credentials" ]Perimeter Medical Imaging AI (OTCQX:PYNKF) reported strong Q2 2025 financial results, with revenue reaching $506,000, a 105% increase year-over-year. The company's Perimeter S-Series OCT device showed significant market traction, with case volumes up 93% YoY and 35% QoQ, having imaged over 3,000 patients to date.
The company's next-generation Perimeter B-Series device, combining AI with OCT technology, achieved positive pivotal trial results with a statistically significant reduction in residual cancer during surgery (p=0.0050). The company completed a two-tranche financing, raising total gross proceeds of approximately $3.8 million.
Q2 2025 financial highlights include a 70% gross margin and reduced operating expenses of $4.3 million, down 22% YoY. Net loss was $3.9 million ($0.04 per share), with cash position at $1.4 million as of June 30, 2025.
Perimeter Medical Imaging AI (OTCQX:PYNKF) reported strong preliminary Q2 2025 results, with expected revenue of $500,000, representing a 100% year-over-year growth. The company projects H1 2025 revenue of $1.0 million, already surpassing full-year 2024 revenue of $846,000.
The company announced a significant 30% reduction in operating costs starting Q3 2025, alongside key leadership appointments including Abbey Goodman as VP of Sales and Paolo DiPasquale as VP of Corporate Development. Additionally, Perimeter established an Industry Advisory Board (IAB) to be chaired by Diana Chan, while COO Tom Boon retired but will continue serving on the IAB.
Q2 2025 highlights include 35% procedure growth, 50% sequential recurring revenue growth, and an expected gross margin of 69%.
Perimeter Medical Imaging AI (OTCQX:PYNKF) announced that Medical City Dallas Hospital, an 899-bed acute care facility, has adopted their S-Series OCT imaging technology for surgical procedures. This adoption follows the hospital's participation in a pivotal trial of Perimeter's next-generation B-Series device, which combines OCT with AI technology for breast-conserving surgeries.
The S-Series OCT technology, FDA-cleared in 2021, provides high-resolution visualization of tissue microstructures at the cellular level, offering superior imaging capabilities compared to traditional methods like X-ray, MRI, or ultrasound. The system is optimized to identify regions of interest in tissue microstructures down to 2mm, making it particularly effective for visualizing surgical margins.
Perimeter Medical Imaging AI (TSXV: PINK, OTCQX: PYNKF) has partnered with Intermountain Health, the largest nonprofit health system in the Intermountain West, through a Development Support Agreement (DSA). The collaboration aims to study the value of Perimeter's Optical Coherence Tomography (OCT) technology and gather data for AI algorithm development.
The initial study will analyze reoperation rates and healthcare costs for breast-conserving surgery (BCS) patients at select hospitals. The partnership will support Perimeter's FDA PMA approval process for their AI-enabled OCT system and potential expansion into other tissue types beyond breast surgery.
Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF), a commercial-stage medical technology company, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 13, 2025, after market close. The company will host a conference call and webcast at 5:00 pm Eastern Time to discuss the results and provide a corporate update. Investors can access the call via 1-800-717-1738 (Canada/US) or 1-646-307-1865 (International). The webcast will be available live and archived on Perimeter's website in the Investors section under "News/Events".